BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23154831)

  • 1. Acquired hypermethylation of the P16INK4A promoter in abdominal paraganglioma: relation to adverse tumor phenotype and predisposing mutation.
    Kiss NB; Muth A; Andreasson A; Juhlin CC; Geli J; Bäckdahl M; Höög A; Wängberg B; Nilsson O; Ahlman H; Larsson C
    Endocr Relat Cancer; 2013 Feb; 20(1):65-78. PubMed ID: 23154831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global and regional CpG methylation in pheochromocytomas and abdominal paragangliomas: association to malignant behavior.
    Geli J; Kiss N; Karimi M; Lee JJ; Bäckdahl M; Ekström TJ; Larsson C
    Clin Cancer Res; 2008 May; 14(9):2551-9. PubMed ID: 18451216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
    Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
    Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylation of the p16INK4A promoter is associated with malignant behavior in abdominal extra-adrenal paragangliomas but not pheochromocytomas.
    Kiss NB; Geli J; Lundberg F; Avci C; Velazquez-Fernandez D; Hashemi J; Weber G; Höög A; Ekström TJ; Bäckdahl M; Larsson C
    Endocr Relat Cancer; 2008 Jun; 15(2):609-21. PubMed ID: 18509008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The VHL gene is epigenetically inactivated in pheochromocytomas and abdominal paragangliomas.
    Andreasson A; Kiss NB; Caramuta S; Sulaiman L; Svahn F; Bäckdahl M; Höög A; Juhlin CC; Larsson C
    Epigenetics; 2013 Dec; 8(12):1347-54. PubMed ID: 24149047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma-Case Report and Review of the Literature.
    Tong A; Li M; Cui Y; Ma X; Wang H; Li Y
    Front Endocrinol (Lausanne); 2020; 11():61. PubMed ID: 32132978
    [No Abstract]   [Full Text] [Related]  

  • 7. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma.
    Assadipour Y; Sadowski SM; Alimchandani M; Quezado M; Steinberg SM; Nilubol N; Patel D; Prodanov T; Pacak K; Kebebew E
    Surgery; 2017 Jan; 161(1):230-239. PubMed ID: 27839933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Ras effectors NORE1A and RASSF1A are frequently inactivated in pheochromocytoma and abdominal paraganglioma.
    Geli J; Kiss N; Lanner F; Foukakis T; Natalishvili N; Larsson O; Kogner P; Höög A; Clark GJ; Ekström TJ; Bäckdahl M; Farnebo F; Larsson C
    Endocr Relat Cancer; 2007 Mar; 14(1):125-34. PubMed ID: 17395981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative global and gene-specific promoter methylation in relation to biological properties of neuroblastomas.
    Kiss NB; Kogner P; Johnsen JI; Martinsson T; Larsson C; Geli J
    BMC Med Genet; 2012 Sep; 13():83. PubMed ID: 22984959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling.
    Lindsey JC; Lusher ME; Anderton JA; Bailey S; Gilbertson RJ; Pearson AD; Ellison DW; Clifford SC
    Carcinogenesis; 2004 May; 25(5):661-8. PubMed ID: 14688019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
    Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
    Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GIPC2 is an endocrine-specific tumor suppressor gene for both sporadic and hereditary tumors of RET- and SDHB-, but not VHL-associated clusters of pheochromocytoma/paraganglioma.
    Dong Y; Huang Y; Fan C; Wang L; Zhang R; Li W; Guo Z; Wang D; Zheng Z
    Cell Death Dis; 2021 May; 12(5):444. PubMed ID: 33947839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations.
    King KS; Prodanov T; Kantorovich V; Fojo T; Hewitt JK; Zacharin M; Wesley R; Lodish M; Raygada M; Gimenez-Roqueplo AP; McCormack S; Eisenhofer G; Milosevic D; Kebebew E; Stratakis CA; Pacak K
    J Clin Oncol; 2011 Nov; 29(31):4137-42. PubMed ID: 21969497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
    Astuti D; Agathanggelou A; Honorio S; Dallol A; Martinsson T; Kogner P; Cummins C; Neumann HP; Voutilainen R; Dahia P; Eng C; Maher ER; Latif F
    Oncogene; 2001 Nov; 20(51):7573-7. PubMed ID: 11709729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma.
    Job S; Draskovic I; Burnichon N; Buffet A; Cros J; Lépine C; Venisse A; Robidel E; Verkarre V; Meatchi T; Sibony M; Amar L; Bertherat J; de Reyniès A; Londoño-Vallejo A; Favier J; Castro-Vega LJ; Gimenez-Roqueplo AP
    Clin Cancer Res; 2019 Jan; 25(2):760-770. PubMed ID: 30301828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline mutations and genotype-phenotype correlation in Asian Indian patients with pheochromocytoma and paraganglioma.
    Pandit R; Khadilkar K; Sarathi V; Kasaliwal R; Goroshi M; Khare S; Nair S; Raghavan V; Dalvi A; Hira P; Fernandes G; Sathe P; Rojekar A; Malhotra G; Bakshi G; Prakash G; Bhansali A; Walia R; Kamalanathan S; Sahoo J; Desai A; Bhagwat N; Mappa P; Rajput R; Chandrashekhar SR; Shivane V; Menon P; Lila A; Bandgar T; Shah N
    Eur J Endocrinol; 2016 Oct; 175(4):311-23. PubMed ID: 27539324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SDH mutations establish a hypermethylator phenotype in paraganglioma.
    Letouzé E; Martinelli C; Loriot C; Burnichon N; Abermil N; Ottolenghi C; Janin M; Menara M; Nguyen AT; Benit P; Buffet A; Marcaillou C; Bertherat J; Amar L; Rustin P; De Reyniès A; Gimenez-Roqueplo AP; Favier J
    Cancer Cell; 2013 Jun; 23(6):739-52. PubMed ID: 23707781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline mutations and genotype-phenotype correlations in patients with apparently sporadic pheochromocytoma/paraganglioma in Korea.
    Kim JH; Seong MW; Lee KE; Choi HJ; Ku EJ; Bae JH; Park SS; Choi SH; Kim SW; Shin C; Kim SY
    Clin Genet; 2014 Nov; 86(5):482-6. PubMed ID: 24134185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes.
    Gill AJ; Benn DE; Chou A; Clarkson A; Muljono A; Meyer-Rochow GY; Richardson AL; Sidhu SB; Robinson BG; Clifton-Bligh RJ
    Hum Pathol; 2010 Jun; 41(6):805-14. PubMed ID: 20236688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations.
    Bernardo-Castiñeira C; Valdés N; Celada L; Martinez ASJ; Sáenz-de-Santa-María I; Bayón GF; Fernández AF; Sierra MI; Fraga MF; Astudillo A; Jiménez-Fonseca P; Rial JC; Hevia MÁ; Turienzo E; Bernardo C; Forga L; Tena I; Molina-Garrido MJ; Cacho L; Villabona C; Serrano T; Scola B; Chirivella I; Del Olmo M; Menéndez CL; Navarro E; Tous M; Vallejo A; Athimulam S; Bancos I; Suarez C; Chiara MD
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5673-5692. PubMed ID: 31216007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.